June 2, 2020: CalciMedica Announces Robert N. Wilson, Former J&J Vice Chairman as Co-Chairman of the Board of Directors and Eric Roberts as Vice Chairman

May 22, 2020: CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora in Patients with Severe COVID-19 Pneumonia

May 22, 2020: CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

May 21, 2020: CalciMedica Announces That FDA Has Strongly Recommended Moving to a Blinded Placebo-Controlled Trial With Auxora in Patients with Severe COVID-19 Pneumonia

May 20, 2020: Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

January 23, 2020: Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

December 9, 2020: Merck to Acquire ArQule For $2.7 Billion

November 8, 2019: HCV Viral Kinetic Analysis Predicts Shorter Treatment duration with AT-527, a Purine Nucleotide Prodrug with Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects Regardless of Cirrhosis Status

August 6, 2019: Leap Presents Positive Clinical Results for the Combination of DKN-01 Plus Keytruda

October 3, 2018: Stryker Completes Acquisition of Invuity, Inc.

April 12, 2018: Atea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C

November 15, 2017: Leap Therapeutics Offers $18 Million Private Placement Offering

August 3, 2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos

May 31, 2016: Jazz Pharmaceuticals Announces Agreement to Acquire Celator Pharmaceuticals for $1.5 Billion

March 30, 2016: Jazz Pharmaceuticals Announces FDA Approval of Defitelio (Defibrotide) for Treatment of Hepatic Veno-Occlusive Disease

March 14, 2016: Celator Pharmaceuticals Announces Statistically Significant Improvement in Overall Survival in Phase III Trial for Vyxeos (CPX-351) in High-Risk AML

June 24, 2015: Celator Pharmaceuticals Announces Positive Response Rate Results From Phase III Study of CPX-351 in High-Risk AML Patients Demonstrating a 43% Relative Improvement

June 15, 2015: Invuity Completes $55 Million IPO

March 16, 2015: Anthera Announces Completion of Intermin Analysis for Phase III trial with Blisibimod in IgA Nepropathy

February 10, 2015: Anthera Announces Completion of Interim Analysis for Phase III Trial With Blisibimod in Lupus

December 19, 2013: Gentium Announces Sale to Jazz Pharmaceuticals for $1 Billion

August 21, 2013: Regado Completes $55 Million IPO

April 30, 2013: Celator Pharmaceuticals Raises $32.5 Million

June 14, 2012: Invuity Raises $25 Million in Series D Funding

July 17, 2012: Vivus Announces FDA Approval of Once Daily Qsymia for Obesity

January 17, 2012: Arqule Announces Tivantinib Meets Primary Endpoint Extending TTP in Phase II Trial in Hepatocellular Carcinoma